Overview of fusion tags for recombinant proteins

Кособокова, Е. Н.; Skrypnik, K. A.; Косоруков, В. С.

doi:10.1134/s0006297916030019

Cited by 71 publications

(37 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because VPS35 is a protein that acts as a platform to which other retromer proteins bind, we next tagged the human VPS35 with HA, since it is smaller than GFP and less likely to interfere with VPS35’s function. This size difference has also been reported to influence expression levels 13–17 . We find that AAV9-VPS35-HA, delivered at similar doses, caused higher total VPS35 expression than AAV9-VPS35-GFP (Fig.…”

Section: Resultsmentioning

confidence: 77%

Retromer repletion with AAV9-VPS35 restores endosomal function in the mouse hippocampus

Qureshi

Berman

Klein

et al. 2019

Preprint

View full text Add to dashboard Cite

Retromer has emerged as a master conductor of endosomal trafficking, and VPS35 and other retromer-related proteins are found to be deficient in late-onset Alzheimer's disease (AD). Depleting VPS35 in neurons impairs retromer function, affecting for example the trafficking of the amyloid-precursor protein (APP) and the glutamate receptor GluA1. Whether VPS35 repletion, after chronic in vivo depletion, can rescue these impairments remains unknown. Here we set out to address this question by using a viral vector approach for VPS35 repletion. First, we completed a series of studies using neuronal cultures in order to optimize AAV9-VPS35 delivery, and to understand how exogenous VPS35 expression affects its endogenous levels as well as its binding to other retromer proteins. Next, we completed a series of studies in wildtype mice to determine the optimum protocol for in vivo delivery of AAV9-VPS35 to the hippocampus. We relied on this information to deliver AAV9-VPS35 to the hippocampus of mice genetically engineered to have chronic, neuronal-selective, VPS35 depletion.VPS35 repletion in the hippocampus was found to normalize APP cleavage and to restore glutamate receptor levels. Unexpectedly, chronic VPS35 depletion in neurons caused glial activation, similar to the pattern observed in AD, which was also partially normalized by VPS35 repletion. Taken together, these studies strengthen the mechanistic link between retromer and AD, and have therapeutic implications.

show abstract

Section: Resultsmentioning

confidence: 77%

Retromer repletion with AAV9-VPS35 restores endosomal function in the mouse hippocampus

Qureshi

Berman

Klein

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…There are two other aspects to bear in mind: the toxicity of the AMP for the host and the high instability and susceptibility of peptides to degradation by proteases. To overcome this, AMPs can be synthesized in a form that is fused to another protein (fusion proteins) or in inactive forms (Kosobokova et al, 2016) initially.…”

Section: Recombinant Production Of Afpsmentioning

confidence: 99%

Antifungal Peptides as Therapeutic Agents

Ullivarri

Arbulu

García-Gutiérrez

et al. 2020

Front. Cell. Infect. Microbiol.

164

132

View full text Add to dashboard Cite

Fungi have been used since ancient times in food and beverage-making processes and, more recently, have been harnessed for the production of antibiotics and in processes of relevance to the bioeconomy. Moreover, they are starting to gain attention as a key component of the human microbiome. However, fungi are also responsible for human infections. The incidence of community-acquired and nosocomial fungal infections has increased considerably in recent decades. Antibiotic resistance development, the increasing number of immunodeficiency-and/or immunosuppression-related diseases and limited therapeutic options available are triggering the search for novel alternatives. These new antifungals should be less toxic for the host, with targeted or broader antimicrobial spectra (for diseases of known and unknown etiology, respectively) and modes of actions that limit the potential for the emergence of resistance among pathogenic fungi. Given these criteria, antimicrobial peptides with antifungal properties, i.e., antifungal peptides (AFPs), have emerged as powerful candidates due to their efficacy and high selectivity. In this review, we provide an overview of the bioactivity and classification of AFPs (natural and synthetic) as well as their mode of action and advantages over current antifungal drugs. Additionally, natural, heterologous and synthetic production of AFPs with a view to greater levels of exploitation is discussed. Finally, we evaluate the current and potential applications of these peptides, along with the future challenges relating to antifungal treatments.

show abstract

“…However, in literature dealing with solving the problems related to operations research there is no explanation of what the efficiency is [6], there is no definition of «technological operation» and «purpose of operation» [7], there is no classification of operations in principle [8], the abstract concept of «operation», with very few exceptions, is used only in the title [9].…”

Section: Determination Of the Class Of Dynamic Models Of Target Operamentioning

confidence: 99%